Previous 10 | Next 10 |
Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings PR Newswire MARLBOROUGH, Mass. , April 29, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of i...
Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1 Data presented at the AACR Annual Meeting 2021 PR Newswire MARLBOROUGH, Mass. , April 10, 2021 /PRNewswire/ -...
Nova LifeStyle (NVFY) +231%.Siebert Financial (SIEB) +63% on Q4 results.Vir Biotechnology (VIR) +60% as its and GSK's COVID-19 antibody drug reduces hospitalization, death by 85%.OrganiGram Holdings (OGI) +40% on cannabis product deal with British American Tobacco.China HGS Rea...
Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting PR Newswire MARLBOROUGH, Mass. , March 11, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a bio...
Phio Pharmaceuticals (PHIO) shares jump nearly 12% premarket after announcing that it has entered into a clinical development collaboration with AgonOx to develop novel T cell-based cancer immunotherapies using Phio's lead INTASYL based product candidate PH-762 and AgonOx's "double ...
ASLAN Pharmaceuticals Limited (ASLN) +71% as ASLAN004 shows positive effect in atopic dermatitis.Apollo Endosurgery (APEN) +47% after receiving a Breakthrough Device Designation from the USFDA for the Orbera® Intragastric Balloon.electroCore (ECOR) +39% on exclusive distri...
Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies PR Newswire MARLBOROUGH, Mass. , March 1, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnolog...
Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th PR Newswire MARLBOROUGH, Mass. , Feb. 23, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next...
4 Biotech Penny Stocks to Watch Right Now Over the course of the past year, investors have focused heavily on biotech penny stocks . Now, this makes sense given the pandemic and the massive capital investments into biotech as a result. But now, a year after the pandemic began, inves...
Phio Pharmaceuticals (PHIO) announces the closing of its previously announced registered direct offering of 2.2M shares at a price of $3.42/share with gross proceeds of about $7.7M.The company intends to use the net proceeds from the offering for general working capital needs, including the d...
News, Short Squeeze, Breakout and More Instantly...
Phio Pharmaceuticals Corp. Company Name:
PHIO Stock Symbol:
NASDAQ Market:
Phio Pharmaceuticals Corp. Website:
Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells...
Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to ...
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced i...